Screening for prostate cancer (Q24201690)

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Results of the three rounds of the Finnish Prostate Cancer Screening Trial--the incidence of advanced cancer is decreased by screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-cancer mortality at 11 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Costs and benefits of early detection of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Randomised prostate cancer screening trial: 20 year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Cumulative incidence of false-positive results in repeated, multimodal cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

15-year followup of a population based prostate cancer screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Health risk behaviors and prostate specific antigen awareness among men in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50--66 years. Implications for sampling order

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Volume adjustment for intermediate prostate-specific antigen values in a screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Population-based case-control study of PSA and DRE screening on prostate cancer mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

A prospective study of trans-fatty acid levels in blood and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

PSA doubling time as a predictor of the outcome of random prostate biopsies prompted by isolated PSA elevation in subjects referred to an outpatient biopsy facility in a routine clinical scenario

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

What will the emperor say? Screening for prostate cancer as of 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Promoting prostate-specific antigen informed decision-making. Evaluating two community-level interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Short-term effects of population-based screening for prostate cancer on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Statistical issues in the evaluation of screening and early detection modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Continuity of care and cancer screening among health plan enrollees

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-specific antigen kinetics in localized and advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Risk of developing prostate cancer in the future: overview of prognostic biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Recruiting older African American men to a cancer screening trial (the AAMEN Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Effects of baseline comorbidities on cancer screening trial adherence among older African American men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

21 January 2018

Update on PSA testing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Economic evaluation of prostate cancer screening with prostate-specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Online spaced education to teach urology to medical students: a multi-institutional randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer in Dutch hereditary prostate cancer families

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

False-positive screening results in the Finnish prostate cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Active surveillance for prostate cancer: trials and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Low-literacy interventions to promote discussion of prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer update: 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

European randomized study of prostate cancer screening: first-year results of the Finnish trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Three-year results of the Finnish prostate cancer screening trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Family history and prostate cancer screening with prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Second round results of the Finnish population-based prostate cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-specific antigen screening and mortality from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Accuracy of self-reported cancer-screening histories: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Nomogram use for the prediction of indolent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer--to screen, or not to screen, is that the question?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Defining increased future risk for prostate cancer: evidence from a population based screening cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Does educational printed material manage to change compliance with prostate cancer screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Influence of a patient decision aid on decisional conflict related to PSA testing: a structural equation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Does the level of prostate cancer risk affect cancer prevention with finasteride?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Lead time associated with screening for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Towards an optimal interval for prostate cancer screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The use of PSA as biomarker in nutritional intervention studies of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for carcinoma of the prostate in a randomly selected population using duplicate digital rectal examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Practical follow-up of a patient treated with finasteride in screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Serendipity in detecting disease in low prostate-specific antigen ranges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Should we replace the Gleason score with the amount of high-grade prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: the Olmsted County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Impact of pretest on posttest knowledge scores with a Solomon Four research design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Endogenous sex hormones and the risk of prostate cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

5-alpha-reductase inhibitors for prostate cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Willingness to pay for mass screening for prostate cancer: a contingent valuation survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The Japanese guideline for prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Quality-of-life effects of prostate-specific antigen screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Mortality and prostate cancer risk in 19,598 men after surgery for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate specific antigen for early detection of prostate cancer: longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Outcomes of localized prostate cancer following conservative management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Population screening for prostate cancer: an overview of available studies and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Decision aids for people facing health treatment or screening decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

The story of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

État des lieux et facteurs de participation à l’étude européenne ERSPC de dépistage randomisé du cancer de la prostate par dosage sérique de l’antigène prostatique spécifique : départements français du Tarn et de l’Hérault

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Chronic hypoxia, physical exercise and PSA: correlation during high-altitude trekking (2004 K2 expedition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

European randomized study of screening for prostate cancer--the Rotterdam pilot studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Does localized prostate cancer exist?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

[Early detection of prostate cancer in Germany. A study of a representative random sample of the population]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Lead-time in the European Randomised Study of Screening for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

False-positive screening results in the European randomized study of screening for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate cancer detection is also relevant in low prostate specific antigen ranges

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Words of wisdom. Re: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam). Wolters T, Roobol MJ, Bangma CH, Schröder PH

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Comparison of Prostate Specific Antigen Velocity in Screened Versus Referred Patients With Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

[Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Diagnostic Methods in the Detection of Prostate Cancer: A Study of a Randomly Selected Population of 2,400 Men

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate-specific antigen as a screening test. The Netherlands experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate cancer epidemiology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

"Screening for prostate cancer"

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Screening for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Screening for prostate cancer: evidence and perspectives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Effect of hemodialysis on serum complexed prostate-specific antigen levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

The European Randomized Study of Screening for Prostate Cancer (ERSPC)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Monitoring the ERSPC trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Management of lower urinary tract symptoms in men: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Prostate cancer screening with prostate-specific antigen in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Age and racial distribution of prostatic intraepithelial neoplasia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

[Is the mass screening for prostate cancer justifiable?]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Cancer screening in Queensland men

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004720.PUB3

7 January 2021

10.1002/14651858.CD004720.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23440794

1 reference

Consolidated OpenCitations Corpus – April 2017